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The recent appearance of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has affected millions of 
people around the world and caused a global pandemic of 
coronavirus disease 2019 (COVID-19). It has been suggested 
that uncontrolled, exaggerated inflammation contributes 
to the adverse outcomes of COVID-19. In this review, 
we summarize our current understanding of the innate 
immune response elicited by SARS-CoV-2 infection and the 
hyperinflammation that contributes to disease severity and 
death. We also discuss the immunological determinants 
behind COVID-19 severity and propose a rationale for the 
underlying mechanisms.
Keywords: COVID-19, cytokine storm, immunoparalysis, 
inflammatory cytokines, innate immune response 
INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in-
fection, is an ongoing global pandemic. As of March 2021, 
more than 120 million patients have been confirmed, and 
the number of deaths from COVID-19 has risen to more 
than 2.7 million. Symptoms of COVID-19 can range from 
none to life-threatening diseases and are clinically heteroge-
neous among different patient groups (Del Valle et al., 2020; 
Merad and Martin, 2020; Vabret et al., 2020). Since its first 
appearance in Wuhan in December 2019, numerous efforts 
and studies have shown that host immune responses and 
immune-related symptoms are distinct between asymptom-
atic and severe COVID-19 patients, and dysregulation of the 
immune response may explicate the severity of COVID-19 
(Brodin, 2021). Notably, emerging evidence suggests that se-
vere COVID-19 presents with high levels of pro-inflammatory 
cytokines and is strongly associated with a hyperinflammatory 
response commonly referred to as a “cytokine storm” (Fajgen-
baum and June, 2020). Inflammation is a beneficial part of 
the immune defenses against infection; nevertheless, exces-
sive pro-inflammatory cytokines frequently exacerbate collat-
eral tissue damages, increasing mortality and prolonging the 
disease (Consiglio et al., 2020; Fajgenbaum and June, 2020). 
Therefore, current treatments focus on managing the in-
flammation caused by SARS-CoV-2 infection, while vaccines 
and anti-viral agents are developed. Moreover, treatments 
targeting inflammatory mediators may have clinical benefits, 
as evidenced by the success of a recently trialed drug, dexa-
methasone (RECOVERY Collaborative Group, 2021). From 
this viewpoint, we summarize the changes in innate immune 
cells seen in moderate and severe COVID-19 and highlight 
the roles of pro-inflammatory cytokines and type I interferons 
(IFNs) in the clinical outcomes. We also discuss the potential 
mechanisms underlying the immunological determinants of 
COVID-19 severity in terms of cross-regulation and immuno-
paralysis.
Mol. Cells 2021; 44(6): 384-391  385
The Dysregulated Innate Immune Response in COVID-19
Sung Ho Park
INNATE IMMUNE SENSING AND INFLAMMATORY 
RESPONSE IN COVID-19
The innate immune cells serve as the first line of host defense 
and are essential for a rigorous immunity to viruses. These 
cells, which include macrophages, monocytes, neutrophils, 
and dendritic cells (DCs), respond to pathogens and pro-
duce cytokines that activate the adaptive immune response 
(Cho et al., 2020; McNab et al., 2015). RNA viruses such as 
SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syn-
drome (MERS) is identified by various pattern-recognition 
receptors, including Toll-like receptors (TLRs) and RIG-I-like 
receptors (RLRs), and induce the type I IFN responses and 
IFN-stimulated gene (ISG) expression. Most host cells express 
cytoplasmic RLRs, whereas TLRs (TLR3, 7, and 8) are gener-
ally expressed in the endosomes of innate immune cells. In 
addition, certain 2'-5'-oligoadenylate synthetase (OAS) and 
interferon induced protein with tetratricopeptide repeats 
(IFIT) family proteins can directly sense viral RNA and are 
associated with antiviral defenses (Park and Iwasaki, 2020; 
Schoggins and Rice, 2011). Innate immune sensing of virus 
triggers subsequent downstream signaling cascades through 
the adaptor molecules MyD88 (for TLR7, TLR8) and TRIF (for 
TLR3). Mice deficient in MyD88 or TRIF are highly susceptible 
to SARS-CoV and exhibit delayed viral clearance, indicating 
these adaptor proteins are required to protect the host from 
coronavirus infections (Sheahan et al., 2008; Totura et al., 
2015). Activation of NF-κB and IRF3/7 signaling mediated by 
MyD88 and TRIF initiates the production of pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF), interleukin 
(IL)-6, IL-1β and type I/III IFNs. Type I/III IFNs, including IFNα, 
IFNβ, IFNω and IFNλ, rapidly induce and orchestrate antiviral 
programs via the JAK and STAT signaling pathway and ISG 
expression (Ivashkiv and Donlin, 2014; McNab et al., 2015). 
Notably, the NF-κB–mediated antiviral response involves the 
activation, recruitment, and coordination of various immune 
cells orchestrated primarily by pro-inflammatory cytokines and 
chemokines (Sokol and Luster, 2015). Thus, in addition to IFN 
responses, pro-inflammatory responses are indispensable for 
a successful antiviral defense, and the balance between IFN 
and pro-inflammatory responses in target cells potentiates 
the adaptive immune response and may signify the severity 
of COVID-19 pathogenesis.
CYTOKINE STORMS AND INNATE IMMUNE 
PHENOTYPES IN SEVERE COVID-19
Increasing evidence indicates that a dysregulated inflamma-
Fig. 1. Inflammatory mediators and innate immune responses during COVID-19 infection. Patients with severe COVID-19 exhibit 
high levels of pro-inflammatory cytokines, causing a cytokine storm and collateral tissue damages in the late phase. Innate immune 
cells in severe COVID-19 have the prominent feature of higher gene expression of inflammatory mediators and impaired responses to 
subsequent stimuli. PPRs, pattern recognition receptors; ARSD, acute respiratory distress syndrome.
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tory response to SARS-CoV-2 is responsible for severe pa-
thology, virus-induced severe complications, and mortality. In 
patients with severe COVID-19, aggressive activation of the 
innate immune system results in a cytokine storm and con-
tributes to lung injury, acute respiratory distress syndrome, 
and multi-organ failure (Consiglio et al., 2020; Fajgenbaum 
and June, 2020). While the molecular and mechanistic defini-
tions of a cytokine storm are unclear, it is typically associated 
with a hyperinflammatory response that causes collateral tis-
sue damages and is clinically characterized by hemodynamic 
instability, hyperferritinemia, and multiorgan failure (Fajgen-
baum and June, 2020; Merad and Martin, 2020; RECOVERY 
Collaborative Group, 2021). Although the levels of pro-in-
flammatory cytokines differed to some extent in the studies 
reported to date, in general, circulating cytokines in patients 
with severe COVID-19 include the major pro-inflammatory 
cytokines such as IL-6, TNF, IL-1β, IL-18, IP-10, IFNγ, CCL2, 
CCL5, CXCL8, and CXCL10 (Abers et al., 2021; Blanco-Me-
lo et al., 2020; Lee et al., 2020; Lucas et al., 2020; Schul-
te-Schrepping et al., 2020; Zhou et al., 2020a; 2020b) (Fig. 
1, Table 1). For example, high serum IL-6 and TNF levels were 
found in most studies, and even after adjusting the disease 
severity for risk factors such as inflammation markers, age, 
sex, and hypoxia, elevated IL-6 and TNF have been shown to 
be independent and important predictors of disease sever-
ity and patient survival (Del Valle et al., 2020). In addition, 
inflammasome-mediated cytokines, such as IL-1β and IL-18, 
were also higher in patients with severe COVID-19 than in 
those with moderate disease (Rodrigues et al., 2021). Besides 
pro-inflammatory cytokines, both immune complement C5a-
C5aR1 and long pentraxin 3 (PTX3) have been associated 
with adverse outcomes of SARS-CoV-2 infection (Brunetta 
et al., 2021; Carvelli et al., 2020). Plasma concentrations of 
soluble C5a and PTX3 were increased in proportion to the se-
verity of COVID-19 and contribute to systemic inflammation 
and thrombosis. Corresponding to the high levels of circulat-
ing inflammatory mediators, gene expression levels of pro-in-
flammatory cytokines in blood immune cells were greatly 
enhanced in patients with severe COVID-19 (Arunachalam 
et al., 2020; Bernardes et al., 2020; Giamarellos-Bourboulis 
et al., 2020; Hadjadj et al., 2020; Lee et al., 2020; Lucas et 
al., 2020; Schulte-Schrepping et al., 2020; Silvin et al., 2020; 
Wilk et al., 2020; Zhu et al., 2020). These transcriptional 
differences associated with various symptoms suggest that 
peripheral immune activation contributes to the hyperin-
flammatory phenotype of patients with severe COVID-19. A 
heightened inflammatory phenotype, which is proportional 
to lung injury and respiratory failure in critical cases, is also 
observed in both the lungs and bronchoalveolar lavage fluid 
(BALF) (Bost et al., 2020; Chua et al., 2020; Liao et al., 2020). 
Single-cell RNA-seq (scRNA-seq) data showed that SARS-
CoV-2 primarily infects lung epithelial cells and macrophages, 
but only some subtypes of macrophages and monocytes in 
the BALF exhibited higher levels of pro-inflammatory cytokine 
Table 1. Inflammatory markers in COVID-19 patients
Inflammatory 
marker
Main cell source In COVID-19 patients Reference
IL-6 Macrophages, T cells, 
 endothelial cells
Independent and significant predictors of 
disease severity and death 
Abers et al., 2021; Arunachalam et al., 2020; 
Bernardes et al., 2020; Brunetta et al., 
2021; Del Valle et al., 2020; Galani et al., 
2021; Giamarellos-Bourboulis et al., 2020; 
Hadjadj et al., 2020; Laing et al., 2020; Lu-
cas et al., 2020; Mann et al., 2020; Ren et 
al., 2021; Ramlall et al., 2020; Rodrigues et 
al., 2021; Silvin et al., 2020; Su et al., 2020
TNF Macrophges, T cells, NK cells Correlated with disease severity and poor 
prognosis
Arunachalam et al., 2020; Bernardes et al., 
2020; Blanco-Melo et al., 2020; Chua et 
al., 2020; Del Valle et al., 2020; Galani et 
al., 2021; Giamarellos-Bourboulis et al., 
2020; Hadjadj et al., 2020; Karki et al., 
2021; Lee et al., 2020; Ren et al., 2021
IFNγ Th1 cells, cytotoxic T cells and 
NK cells
Shown to be increased in severe cases Grant et al., 2021; Karki et al., 2021; Lucas 
et al., 2020; Ren et al., 2021
IL-1β Macrophages, epithelial cells Associated with cytokine storms Bernardes et al., 2020; Chua et al., 2020; 
Grant et al., 2021; Lee et al., 2020; Ren et 
al., 2021
IL-18 Monocytes, macrophages, 
dendritic cells
Positively correlated with disease severity Lucas et al., 2020; Rodrigues et al., 2021
IL-8 (CXCL8) Macrophages, epithelial cells Correlated with disease seveirty and  
associated with cytokine storms 
Abers et al., 2021; Blanco-Melo et al., 
2020; Chua et al., 2020; Del Valle et al., 
2020; Galani et al., 2021; Laing et al., 
2020; Silvin et al., 2020; Ren et al., 2021
Complement Hepatocytes, other cells Increased in proportion to the severity of 
COVID-19 
Carvelli et al., 2020; Ramlall et al., 2020
Mol. Cells 2021; 44(6): 384-391  387
The Dysregulated Innate Immune Response in COVID-19
Sung Ho Park
expression (Bost et al., 2020; Chua et al., 2020; Liao et al., 
2020). Therefore, innate immune cells appear to be responsi-
ble for the inflammatory environment in the lungs.
 Innate immune cells, such as monocytes, macrophages, 
and neutrophils, are major producers of the pro-inflam-
matory cytokines associated with COVID-19 and are often 
implicated in the pathogenesis of excessive inflammation 
or cytokine storms in other human diseases (Merad and 
Martin, 2020). A number of scRNA-seq and FACS-based 
studies analyzing peripheral blood mononuclear cells (PB-
MCs) demonstrated that patients with COVID-19 exhibited 
increased numbers of inflammatory or classical monocytes, 
low-density neutrophils, eosinophils, and megakaryocytes 
(Ren et al., 2021), as well as a sharp decrease in the num-
ber and frequency of non-classical monocytes, myeloid DCs 
(mDCs), plasmacytoid DCs (pDCs), and lymphocytes such as 
CD4+ T cells, CD8+ T cells, and natural killer (NK) cells. For 
example, in the PBMCs of COVID-19 patients, non-classical 
monocytes (CD14low CD16hi) are dramatically depleted, while 
classical monocytes, which are marked by their low expres-
sion of human leukocyte antigen DR isotype (HLA-DR), are 
significantly increased, especially in severe cases (Lee et al., 
2020; Mann et al., 2020; Schulte-Schrepping et al., 2020; 
Silvin et al., 2020; Wilk et al., 2020). HLA-DRlow monocytes 
showed low induction of COX-2, the prostaglandin-produc-
ing enzyme, and enhanced expression of Ki-67, a cell cycle 
marker (Mann et al., 2020). Another independent study 
demonstrated that some monocyte subsets display high lev-
els of MAFB, PLBD1, and CD163 (Schulte-Schrepping et al., 
2020), revealing the phenotypic heterogeneity of monocytes 
within the microenvironment during SARS-CoV-2 infection. 
In many inflammatory diseases, inflammatory monocytes 
are actively recruited to the tissues via the high expression of 
multiple chemokine receptors, where they aid in maintaining 
tissue macrophage populations, whereas non-classical mono-
cytes are recruited in fewer numbers (Kapellos et al., 2019). 
Thus, inflammatory monocytes are selectively recruited to 
the lungs by the increased chemokines, which may explain 
the increase in monocyte-derived macrophage counts in the 
lungs and BALF in severely ill patients that result in excessive 
inflammation, lung injury, and respiratory failure. Moreover, 
tissue-resident, alveolar macrophages have been shown to 
be greatly reduced in patients with severe COVID-19 (Bost 
et al., 2020; Grant et al., 2021; Liao et al., 2020), indicating 
the regulation of tissue homeostasis by monocytes and mac-
rophages is profoundly disrupted during viral infection. The 
BALF and PBMCs of patients with severe COVID-19 comprise 
lower proportions of conventional DCs (cDCs) and pDCs, and 
the ratios of cDCs to pDCs are increased in critical cases (Bost 
et al., 2020; Laing et al., 2020; Liao et al., 2020; Zhou et al., 
2020a). These DCs also exhibit functional impairments that 
can lead to dysregulated adaptive immune responses against 
SARS-CoV-2. The number of neutrophils also increases in 
patients with severe COVID-19; recent studies showed that 
immature CD10lowCD101-CXCR+/- neutrophils numbers were 
increased in the blood and lungs, and emergency myelopoi-
esis releases immature and dysfunctional neutrophils in these 
patients (Bernardes et al., 2020; Schulte-Schrepping et al., 
2020). Neutrophil extracellular traps are also found in the 
lungs of COVID-19 patients and may contribute to thrombo-
sis, tissue damage, and inflammation, indicating the potential 
role of neutrophils during SARS-CoV-2 infection (Middleton 
et al., 2020; Radermecker et al., 2020). Together, dysregulat-
ed innate immune responses and heightened inflammatory 
mediators contribute to the clinical observations of COVID-19 
severity, cytokine storms, and critical tissue damage. How-
ever, it is not yet clear how ongoing SARS-CoV-2 replication 
modulates the innate immune responses and causes unre-
solving inflammation and severity.
IMBALANCE AND CROSS-REGULATION BETWEEN 
PRO-INFLAMMATORY CYTOKINES AND IFNs
Upon virus infection, the transient but high production of 
IFNs induces the expression of ISGs and mediates the protec-
tive immune response by inhibiting viral replication (McNab et 
al., 2015). While the induction of high levels of inflammatory 
cytokines is a commonly agreed COVID-19 trait according to 
many studies to date, the role of IFNs remains controversial. 
For example, recent studies showed that SARS-CoV-2, like 
SARS-CoV and MERS-CoV, has the ability to suppress and 
delay the production of type I IFN by infected cells (King and 
Sprent, 2021; Park and Iwasaki, 2020; Shin et al., 2020). Viral 
modulation of IFN productio can be mediated via multiple 
layers of regulation, such as inhibition of innate sensing, IFN 
signaling, and ISG effector function. Accordingly, the scRNA-
seq data for various cell types show that SARS-CoV-2 triggers 
low IFNs and limited (or absent) ISG responses, which are 
accompanied by high viral loads, leading to severe COVID-19 
phenotypes (Blanco-Melo et al., 2020; Combes et al., 2021; 
Hadjadj et al., 2020). The importance of impaired IFN re-
sponses has been further emphasized in recent studies, in 
which inborn errors of type I IFN cell-intrinsic immunity and 
type I IFN neutralizing autoantibodies with a lower viral load 
were strongly associated with patients with life-threatening 
COVID-19 (Bastard et al., 2020; Zhang et al., 2020).
 By contrast, other research groups have reported that pa-
tients with severe COVID-19 exhibited higher levels of type 
I or III IFNs and a strong response to IFNs in the PBMCs and 
BALF, and postmortem, compared to moderate patients 
(Abers et al., 2021; Arunachalam et al., 2020; Bernardes et 
al., 2020; Chua et al., 2020; Galani et al., 2021; Lee et al., 
2020; Lucas et al., 2020; Wilk et al., 2020; Zhu et al., 2020). 
Furthermore, the death rate was correlated with heightened 
levels of type I and III IFNs in patients’ BALF. A longitudinal 
profiling study has shown that the presence of high IFN levels 
for 12 days after the first symptom onset correlated with lon-
ger hospitalizations and higher mortality (Lucas et al., 2020). 
Although more work is needed, studies to date have discov-
ered that ISG expression and IFN signatures are common, 
while type I IFN mRNA and protein levels are relatively low 
in the serum, PBMC, BALF, and lungs of severe COVID-19 
patients. Thus, these observations suggest that patients are 
exposed to IFNs over time, but their IFN responses are dy-
namic and temporal. Additionally, the sustained production 
of IFN in patients with severe COVID-19 are more dependent 
on tissue-resident cells, such as lung epithelial cells, because 
IFN gene expression in immune cells is relatively low, and the 
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proportion of pDCs, major IFN producers, is reduced. Ac-
knowledging the complexity of the IFN response, heightened 
levels of IFNs and ISGs generally correlate with worse cases in 
the late and critical phases of COVID-19, similar to the finding 
of previous studies on SARS and MERS patients (Cameron et 
al., 2007; Park and Iwasaki, 2020). Importantly, untimely type 
I IFN signaling is known to be deleterious through harmful 
pro-inflammatory effects on immunopathology (Ivashkiv and 
Donlin, 2014). This was supported by a recent retrospective 
cohort study of patients with COVID-19, in which IFNα treat-
ment in the late phase led to enhanced inflammation, longer 
hospital stays, and a higher death rate (Wang et al., 2020). 
The balance between pro-inflammatory and IFN responses 
is a critical determinant of severe COVID-19 immunopathol-
ogy. The expression of IFN changes dynamically over time, 
and pro-inflammatory cytokines are maintained at high levels 
in the late phase during SARS-CoV-2 infection. Although 
the relative roles of NF-κB–mediated inflammatory and 
STAT/IRF-dependent IFN responses are still unclear in severe 
COVID-19, cross-regulation between pro-inflammatory cyto-
kines and type I/II IFNs is likely to shape the pathogenic roles 
of cytokines and IFNs.
 In infection and inflammation, priming by type I and II IFNs 
positively or negatively regulates the inflammatory response 
and vice versa (Ivashkiv, 2018; Ivashkiv and Donlin, 2014; Mc-
Nab et al., 2015; Park and Iwasaki, 2020). The roles of IFNs 
via priming effects in enhancing the inflammatory response 
are well established (Fig. 2). Although IFN’s antiviral activities 
are mediated by the canonical JAK-STAT signaling pathway, 
other signaling mechanisms, including NF-κB, AP-1, PI3K-
mTOR, and MAPK, are further activated by IFNs, leading to 
various potential inflammatory responses. This diversity of 
transcription factors activated by IFNs mediates the broad 
effects of IFN-induced signaling and increases the expression 
of genes other than ISG that encode pro-inflammatory cyto-
kines and chemokines. For example, recent studies showed 
there was a positive feedback loop between IFNγ-expressing 
T cells and macrophages in patients with severe COVID-19, 
leading to adverse outcomes (Grant et al., 2021; Karki et 
al., 2021; Silvin et al., 2020; Zhu et al., 2020). Accordingly, 
STAT1/IRF3-dominant signaling pathways, which are key 
regulators of inflammatory and type II IFN responses, were 
more highly activated in COVID-19 compared with influenza 
A virus patients (Zhu et al., 2020). These IFNγ-primed mac-
rophages have several additional salient features not seen 
in conventional ISG expression; they can become hyper-re-
sponsive to subsequent inflammatory stimuli such as TNF, 
IL-1β and ligands for TLRs (Ivashkiv, 2018). Thus, IFNγ-primed 
macrophages may contribute to the production of massive 
amounts of inflammatory cytokines and NF-κB target genes 
in patients with severe COVID-19. In addition, IFNγ-primed 
macrophages have been shown to be refractory to anti-in-
flammatory factors, such as glucocorticoids or IL-10, in a 
gene-specific manner, leading to unresolving inflammation 
and poor tissue healing. Similar to IFNγ, type I IFNs also can 
potentiate the inflammatory response in infection and in-
flammation. For example, most NF-κB–dependent genes of 
inflammatory cytokines are not activated by type I IFNs alone 
(Ivashkiv and Donlin, 2014; McNab et al., 2015), whereas 
cooperative actions between type I IFNs and TNF have been 
shown to enhance the responsiveness against subsequent 
stimuli and increase gene expression of pro-inflammatory 
cytokines in human macrophages (Park et al., 2017). Other 
studies demonstrated that gene expression of IL-6 and iNOS 
is activated by coordinate binding of STAT/IRFs and NF-κB to 
their promoters (Platanitis and Decker, 2018). As features of 
many infectious and inflammatory diseases, the IFN priming 
effects that increase inflammatory cytokine expression are 
mostly mediated by transcriptional and epigenetic repro-
gramming (discussed below).
 There may also be mechanisms by which the high levels 
of inflammatory cytokines in patients with severe COVID-19 
conversely regulate the IFN response. For instance, TNF or 
macrophage colony-stimulating factor (M-CSF) induces the 
IRF1-mediated production of picomolar concentrations of 
IFNβ that results in the potent induction of ISGs (Venkatesh 
et al., 2013; Yarilina et al., 2008). It has been shown that 
IL-1β and prostaglandin E2 can inhibit the expression of type 
I IFN and ISGs during bacterial infection. These inflammatory 
mediators change the quantity and quality of IFN signaling 
and disrupt the timing and duration of the anti-viral response 
relative to virus loads (McNab et al., 2015), as shown in 
mouse models of MERS-CoV infections (Channappanavar et 
al., 2019). In summary, cross-regulation between IFNs and 
pro-inflammatory cytokines can contribute to excessive and 
unrestrained inflammation, which may result in severe clinical 
outcomes in COVID-19 patients. However, the related mech-
anisms involved in COVID-19 have not yet been studied and 
require further elucidation.
IMMUNOPARALYSIS AND INNATE IMMUNE MEMORY
It is interesting that, despite high levels of inflammatory medi-
ators, innate immune cells in patients with severe COVID-19 
are refractory to subsequent stimuli of cytokines or TLR ago-
Fig. 2. IFN priming activates macrophages and reverses the state 
of tolerance. TLR agonists and TNF induce a state of tolerance in 
which chromatin is closed, that is associated with immunoparalysis. 
IFN priming of basal or tolerized macrophages strongly increases 
responsiveness and pro-inflammatory responses by priming and 
opening the chromatin at the non-ISGs locus.
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nists (Fig. 1). CD14+ monocytes isolated from the PBMCs of 
patients with severe COVID-19 exhibited a “tolerized state”, 
in which previous exposure to TLR ligands or cytokines led to 
a transient period of hypo-responsiveness upon subsequent 
stimuli (Arunachalam et al., 2020; Combes et al., 2021; Gia-
marellos-Bourboulis et al., 2020; Schulte-Schrepping et al., 
2020; Zhou et al., 2020a). This “tolerization” involving innate 
immune memory (Netea et al., 2020) is an intrinsic biologi-
cal process that prevents a surge in hyperinflammation and 
adjusts the magnitude and duration of the inflammatory 
response. It is worth noting that macrophage tolerance is not 
an anti-inflammatory or non-inflammatory state, but rather, 
an inflammatory state in which there is no further response 
to subsequent stimuli. Arunachalam et al. (2020) recently 
identified that CD14+ monocytes and myeloid DCs isolated 
from COVID-19 patients produced significantly less TNF and 
IL-6 in response to a bacterial cocktail of lipopolysaccharide 
(LPS), Pam3CSK4, and Flagellin or a viral cocktail of polyIC, 
R848. Similar to that seen in other macrophage tolerance 
models, phosphorylated p65 was decreased in the same 
cells, suggesting canonical inflammatory NF-κB signaling was 
suppressed. The response of pDCs to the viral cocktail was 
also considerably inhibited. Of note, Schulte-Schrepping et al. 
(2020) demonstrated that monocytes isolated from patients 
with severe COVID-19 exhibited stronger tolerization in re-
sponse to LPS, suggesting that the inflammatory responses 
are related to the pathogenic hypo-responsiveness of mono-
cytes. Other independent studies also showed that DCs, PB-
MCs, and CD14+ monocytes isolated from patients were less 
responsive to the pro-inflammatory cytokine cocktail (IL-1β, 
IL-6, TNF, and PGE2) as well as to SARS-CoV-2, respectively 
(Combes et al., 2021; Giamarellos-Bourboulis et al., 2020; 
Zhou et al., 2020a). The occurrence of innate immune cell 
tolerization was further supported by the finding that plasma 
from severe COVID-19 patients had increased levels of bacte-
rial DNA (Arunachalam et al., 2020). These results collectively 
suggest that the severe phenotypes of patients, involving 
cytokine storms, are strongly associated with tolerization in-
duced by infections and certain pro-inflammatory cytokines 
such as TNF. Interestingly, both type I and II IFNs have been 
shown to prevent and reverse macrophage tolerance. Ex 
vivo priming of IFNγ  or IFNα2 abolished LPS- or TNF-induced 
tolerance in human macrophages and monocytes, respec-
tively (Chen and Ivashkiv, 2010; Park et al., 2017). As shown 
in a report in which circulating endotoxin induced strong 
tolerance in sepsis (van der Poll et al., 2017) and abolished 
tolerance in systemic lupus erythematosus (SLE) (Shi et al., 
2014), the magnitude and duration of IFNs in various human 
diseases are likely to be involved in determining macrophage/
monocyte tolerance. Mechanistically, the induction or abro-
gation of tolerance is mediated by transcriptional, epigenetic, 
and metabolic reprogramming (as reviewed elsewhere: Ivash-
kiv, 2018; Netea et al., 2020), leading to the dysregulation 
of the inflammatory responses (Fig. 2). Accordingly, robust 
epigenetic and metabolic changes, which may be associated 
with macrophage tolerance and innate immune memory, 
have recently been reported in COVID-19 patients. Ge-
nome-wide CRISPR screens using SARS-CoV-2 showed that 
genes encoding the SWI/SNF chromatin-remodeling complex 
are pro-viral factors (Wei et al., 2021), and the distinct chro-
matin accessibility changes during virus infection were associ-
ated with COVID-19 severity (Giroux et al., 2020). Alterations 
of metabolic pathways, such as kynurenine, which is linked 
to COVID-19 severity (Nie et al., 2021; Shen et al., 2020) and 
sepsis (van der Poll et al., 2017), were also demonstrated. 
However, our current understanding of the immunoparalysis 
of patients with severe COVID-19 is very limited, and more 
work is needed to establish the immune determinants during 
infection and identify therapeutic targets.
CONCLUDING REMARKS
Despite the many unknowns, the limited success of the 
recent dexamethasone trial implies that excessive inflamma-
tion can be ameliorated in patients with severe COVID-19 
to reduce their clinically critical immunopathology. Further 
clinical trials targeting hyperinflammation with antagonists 
against JAK, IL-1β, IL-6, TNF, and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) in COVID-19 patients are 
ongoing, but it is hoped the results will present potential op-
portunities. The importance of age, sex, and comorbidity as 
determinants of severe COVID-19 is known, but our current 
understanding of the associations between COVID-19 and 
the immune response is very limited. It is also unclear how the 
inflammation observed in COVID-19 that causes long-term 
persistence and high mortality differs from the inflammation 
in other respiratory infections. Thus, broadening our under-
standing of the delicate balance between pro-inflammatory 
cytokines and IFNs will enable the development of effective 
treatments specifically for the hyperinflammation of severe 
COVID-19 without perturbing a wide range of anti-viral host 
defenses. As noted above, timing, duration, and qualitative 
regulation are important parameters in various cytokine ac-
tivities and should be considered before targeting excessive 
inflammation in COVID-19. Importantly, studying the causal 
factors linking inflammatory mediators and clinical heteroge-
neity is a prerequisite for the development of truly predictive 
biomarkers and therapeutics for COVID-19. As more evi-
dence emerges for several factors that manage inflammatory 
responses, drugs that target epigenetic markers on chromatin 
or metabolism pathways are also potential tools for reducing 
hyperinflammation and mortality in patients with COVID-19.
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